Orion partners with Amneal on generics
Finnish drugmaker Orion Corporation (Nasdaq OMX: ORNAV) says it has signed a long-term license agreement with US drugmaker Amneal Pharmaceuticals (NYSE: AMRX), to commercialize Amneal’s generic products in Orion territories.
Under the terms of the agreement, Orion is granted an 0exclusive licence to commercialize and sell Amneal’s generic products in most parts of Europe as well as in Australia and New Zealand.
The initial portfolio will include a mix of generic products currently commercially available in the USA, as well as selected pipeline products now under development. Initial products will be registered throughout Europe, Australia and New Zealand starting in2023, with launches expected over the coming years.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze